| Name | Title | Contact Details |
|---|
Macherey-Nagel is a Easton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.
We cultivate authentic materials without compromise,by harnessing science and nature responsibly by partnering the most innovative minds in science and technology with the finest craftspeople to accelerate the use of cellular agriculture for good.
Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients. Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including a rare form of polycystic ovary syndrome (PCOS).
Leading Research into Solving one of the World`s Largest Drivers of Disease: Inflammation